⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GANX News
Gain Therapeutics, Inc. Common Stock
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
globenewswire.com
GANX
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
globenewswire.com
GANX
Gain Therapeutics to Present at Neuroscience 2025
globenewswire.com
GANX
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
globenewswire.com
GANX
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
globenewswire.com
GANX
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®
globenewswire.com
GANX